The FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two specific types of lymphomas, which are cancers that affect the body’s immune system.
Read more: Ukoniq (umbralisib): Drug Safety Communication - FDA Investigating Possible Increased Risk of Death with Lymphoma